Liebe HTA-Interessierte,

wir freuen uns, Sie darauf hinweisen zu dürfen, dass folgende neue Berichte (online) veröffentlicht wurden:

Policy Briefs:

• Covid-19: HSS/ Horizon Scanning Living Document (v06 September 2020), Teil 1. AIHTA Policy Brief 002.
• CAR-T Cell Therapies. AIHTA Policy Brief 006a.
• ATMPs and Gene Therapies. AIHTA Policy Brief 006b.

Oncology Factsheets:

• Carmustine (Carmustine Obvius®) as conditioning treatment before transplantation in patients with Hodgkin’s lymphoma (HL) and non-Hodgkin’s lymphomas (NHL). Oncology Fact Sheet Nr. 14.
• Acalabrutinib (Calquence®) for the treatment of chronic lymphocytic leukaemia (CLL). Oncology Fact Sheet Nr. 15.
• Avapritinib (Ayvakyt®) for the treatment of gastrointestinal stromal tumours (GIST). Oncology Fact Sheet Nr. 16.
• Belantamab mafodotin (Blenrep®) as monotherapy for the treatment of relapsed or refractory multiple myeloma (MM). Oncology Fact Sheet Nr. 17.
• Durvalumab (Imfinzi®) in combination with etoposide and either carboplatin or cisplatin for the first-line treatment of extensive-stage small cell lung cancer (ES-SCLC). Oncology Fact Sheet Nr. 18.
• Ibrutinib (Imbruvica®) as a single agent or in combination with rituximab or obinutuzumab for the treatment of previously untreated chronic lymphocytic leukaemia (CLL). Oncology Fact Sheet Nr. 19.

Mit freundlichen Grüßen

Ozren Sehic
______________________________________________________________________________

Ozren Sehic, B.A.
Assistenz der Geschäftsführung und Wissenschaftskommunikation
Austrian Institute for Health Technology Assessment
Garnisongasse 7/20, 1090 Vienna
Tel: +43 (0) 1 236 81 19-23
Webseite